IL6 and COVID-19: It is possible that outcomes may have differed with higher baseline use of IL-6 inhibitors, though previous studies of patients hospitalized with COVID-19 (regardless of severity) have not shown any survival benefit of tocilizumab in addition to SOC [40, 41].